three times before dried under vacuum overnight. Chitosan-PF127 was synthesized by adding 10 ml of chitosan solution (200 mg/ml) in deionized (DI) water into 10 ml of the activated PF127 solution (400 mg/ml, in DI water). After reacting for 12 h, this mixture was dialyzed (molecular weight cut off or MWCO: 7 kDa) against DI water for at least 24 h. Lastly, the chitosan-PF127 polymer was freeze-dried for 48 h to remove water for preparing nanoparticles.
Preparation of nanoparticles
To prepare nanoparticles using PF127+DPPC and PNIPAM-B+DPPC, the double emulsion (water in oil in water or W-in-O-in-W) method was used as previously reported with slight modification [2] [3] . Briefly, 5 mg of DPPC and 10 mg of PF127 (or PNIPAM-B) were dissolved in 2 ml of dichloromethane and emulsified with 0.4 ml of DI water for 1 min using a Branson 450
sonifier. This initial emulsion was then emulsified with 4 ml of 2% polyvinyl alcohol (PVA)
solution (in DI water) for 2 min using the Branson 450 sonifier. The resultant mixture was slowly dropped into 6 ml of 0.6% PVA (in DI water) and stirred for 10 min at room temperature. Rotary evaporation was used to remove the organic solvent in the emulsion mixture. The samples prepared with PNIPAM-B could be collected by centrifugation at 13,800 g for 10 min at room temperature and washed twice with DI water to remove non-encapsulated drug. The samples prepared with PF127 had to be collected by using freeze-dry.
To prepare LPN and HCLPN (with or without drug) nanoparticles, the procedure is the same as that mentioned above except that 5 mg of DPPC, 10 mg of PNIPAM-B, and 20 mg of PF127
were dissolved in 2 ml of dichloromethane and 4 ml of the aqueous solution of either PVA (for LPN nanoparticles) or the mixture of chitosan-PF127 and HA (for HCLPN nanoparticles) were used for the second emulsion. The nanoparticles were also collected by centrifugation (13,800 g for 10 min) at room temperature and washed twice with DI water to remove non-encapsulated drug. To prepare nanoparticles without DPPC, the same procedure as that for preparing HCLPN nanoparticles was used except that no DPPC was used during the first W-in-O emulsion.
Encapsulation of DOX in the nanoparticles and in vitro drug release.
The encapsulation efficiency (EE) of DOX in HCLPN nanoparticles was calculated with the following equation:
where W encapsulated represents the amount (in weight) of agents encapsulated into nanoparticles and W fed is the initial total amount of agents fed for encapsulation. The amount of DOX was determined spectrophotometrically using a Beckman Coulter (Indianapolis, IN, USA) DU 800
UV-Vis spectrophotometer based on their absorbance at 486 nm.
To study the in vitro drug release, drug-laden nanoparticles (20-30 mg) dissolved in PBS (pH 7.4) were loaded into dialysis bags (MWCO: 20 kDa) and placed in 50 ml centrifuge tube with 30 ml of PBS solution. The tube was kept at 37 °C and stirred at 110 rpm. The dialysate was collected at various times and the concentration of the released DOX in the dialysate was determined based on its UV-Vis absorbance at 486 nm. For ice-triggered or pH-induced drug release, the nanoparticle solutions in tube were incubated in ice for 5 min or the nanoparticles reconstituted in a pH 5.0 phosphate buffer for 5 min at 5 h. The samples were centrifuged at 13,800 g and the released DOX in the supernatant was determined based on its absorbance at 486 nm. After the ice or low-pH treatment, the samples were centrifuged and reconstituted in PBS (pH 7.4) at 37 °C to monitor drug release for 2 more hours.
Characterization of nanoparticles
The size distribution of nanoparticles in aqueous environment was assessed using a Brookhaven 90 Plus/BI-MAS dynamic light scattering (DLS) instrument with nanoparticle concentration of 1 mg/ml in DI water or phosphate-buffered saline (PBS) at pH 7.4, 6.5 or 5.0. The morphology of nanoparticles was imaged using transmission electron microscopy (TEM). Briefly, the nanoparticles were examined using an FEI (Moorestown, NJ, USA) Tecnai G2 Spirit transmission electron microscope after negatively stained with uranyl acetate solution (2%, w/w).
Cell culture and in vitro cell viability
Multidrug resistant NCI/RES-ADR (ATCC) and A2780ADR ovarian cancer cells were cultured in EMEM and RPMI 1640, respectively, and supplemented with 10% FBS and 1%
penicillin/streptomycin at 37 °C in a humidified 5% CO 2 incubator. To obtain CSC-enriched spheres, single cancer cells of 20,000 cells/ml were obtained and then cultured in 24-well ultralow attachment plates (Corning, Lowell, MA, USA) in 1 ml of CSC medium in each well.
The CSC medium was made of DMEM/F12-K medium supplemented with 5 µg/ml insulin, 20 ng/ml epidermal growth factor (EGF), 20 ng/ml basic fibroblast growth factor (bFGF), 1x B27
(Invitrogen), and 0.4% (w/v) bovine serum albumin (BSA) 4 . After 10 days, the CSC-enriched spheres were collected for further experimental use. In order to maintain the multidrug resistant capability, DOX (1.5 µg/ml) was added in the medium for both the 3D sphere and 2D culture.
To determine the viability of 2D cultured cells, 10,000 cells were cultured in 96-well plates for 12 h, and then treated with various drug formulations for either 24 or 48 h. For quantifying the cell viability in 3D spheres, the spheres cultured in 24-well plates as aforementioned were treated with various drug formulations directly. For the treatments with ice cooling, cells after 12 h of incubation in the plates were cooled on ice for 5 or 10 min and then put back in incubator for further culture. Right before ice cooling, the medium with nanoparticles was collected and replaced with pure medium. Immediately after cooling, the pure medium was removed and the collected medium with nanoparticles was put back to culture with the cells for additional 12 or 36 h (24 or 48 h of culture in total). Cells cultured in pure medium without any treatment are prepared as control. The cell viability after each treatment as compared to control cells was quantified using the Cell Counting Kit-8 (CCK-8) assay according to the manufacturer's instruction by measuring absorbance at 450 nm with a PerkinElmer VICTOR X4Multilabel plate reader.
In vitro imaging
Cells were seeded onto collagen-coated cover glasses (Nunc, Thermo Fisher Scientific Inc., min at room temperature. Afterward, the slides were washed with buffer for four times and covered with anti-fade mounting medium for examination.
TEM imaging of cells
Cells were cultured in the Nunc™ Lab-Tek™ II Chamber Slide™ System (Thermo Fisher Scientific Inc., Waltham, USA) at a density of 1×10 6 cells/ml, and incubated with HCLPN-D nanoparticles for 3 h. Ice treatment was applied in the same way as that for cell viability studies.
Samples were prepared for TEM according to standard procedures and examined using a FEI (Moorestown, NJ, USA) Tecnai G2 Spirit transmission electron microscope.
Flow cytometry
To characterize the expression of CD44, 2D cultured MDA-MB-231 cells, NCI/RES-ADR cells and 3D CSC-enriched spheres were dissociated enzymatically with trypsin/EDTA, and further dissociated by gentle pipetting. Single cells were washed with PBS and incubated with 3% BSA for 3 h to block nonspecific binding, and then stained with CD44-FITC (Invitrogen, Carlsbad, CA) antibodies according to the manufacturer's instructions. Lastly, the stained samples were studied using a BD LSR II Flow Cytometer and the data were analyzed using the BD FACSDiva software.
Animals and xenograft of drug resistant tumors
Athymic female NU/NU nude mice of 6-week old were purchased from Charles River 
In vivo imaging and biodistribution
For in vivo imaging, after the tumor reached ~5 mm in long diameter, mice were injected with 100 µl of saline, free ICG, and HCLPN-G nanoparticles (ICG: 50 µg) in 100 µl of saline. After intravenous injection via the tail vein, the mice were taken at 1, 3, 6, and 9 h using a PerkinElmer (Waltham, MA, USA) IVIS instrument. The excitation at 780 nm was applied and the fluorescence emission of ICG was collected with an 830 nm filter. After imaging, the mice were sacrificed and tumor, liver, kidney, lung, spleen, and heart were collected for further ex vivo fluorescence imaging of ICG using the same IVIS instrument.
In vivo antitumor efficacy and safety
After tumors reached ~5 mm in long diameter, mice were treated with 100 µl of saline or HCLPN nanoparticles, DOX without or with ice treatment for 10 min (DOX: 3 mg/kg body weight), and HCLPN-D nanoparticles without and with ice treatment for 10 min (DOX: 3 mg/kg body weight). A total of 100 µl of saline was used as the carrier for all the drug formulations and mice were injected with various drug formulations for 5 times in total on days 1, 8, 15, 22 and 29. The ice treatment was conducted at 12 h after the intravenous drug injection. Immediately before and after ice treatment, mice were checked for the whole body temperature using infrared thermography. Tumor size was measured every 7 days using a caliper. The tumor volume (V)
, where L is long diameter and W is short diameter. The mice were euthanized on day 59 after drug injection. Tumors, livers, lungs, hearts, spleens, and kidneys were collected, formalin fixed, paraffin embedded, and haematoxylin&eosin (H&E) stained for further standard histological analysis.
For establishing the orthotopic metastasis model of ovarian cancer, NCI/RES-ADR cells
were suspended at 1 x 10 7 cells/ml in a mixture (1:1) of 1x PBS and matrigel (BD Biosciences, MD, USA). A total of 2 x 10 6 cells in 200 µl of the mixture were intraperitoneally injected into peritoneal cavity of each nude mouse of 7-week-old on day 1. Mice were treated with 100 µl of saline, free DOX (DOX: 3 mg/kg body weight), and HCLPN-D nanoparticles (DOX: 3 mg/kg body weight) at days 7, 14 and 21. All the mice received ice treatment at 12 h after intraperitoneal injection of the saline and drug formulations. Immediately before and after ice treatment, mice were checked for their body temperature using infrared thermography. All mice were euthanized on day 32. Tumors, livers, lungs, hearts, spleens, and kidneys were collected, formalin fixed, paraffin embedded, and H&E stained for further standard histological analysis.
Statistical analysis
All data are reported as mean ± standard deviation (SD) from at least three independent runs. The
Kruskal-Wallis H test and the Mann-Whitney U test were used to assess the overall among-group and two-group differences, respectively. All statistical analyses were carried out with the IBM (Chicago, IL, USA) SPSS 22 software. Figure S1 . TEM image of nanoparticles prepared by using PF127 and PNIPAM-B (without the lipid DPPC). The multicore-shell structure of the HCLPN nanoparticles is not evident in the these nanoparticles, suggesting the lipid used during the first time emulsion may interact with PF127 and PNIPAM-B to form the multicore structure in the HCLPN nanoparticles. The tissues were stained by hematoxylin and eosin (H&E). The data show that although the treatment with free DOX via intravenous injection could induce significant damage to heart, liver, kidney, and lung, no appreciable damage to these critical organs could been observed for the HCLPN-D+L treatment. These observations are in accordance with the body weight data shown in Figure 6h . Figure S35 . Histology images of critical organs collected on day 32 after different treatments. The tissues were stained by hematoxylin and eosin (H&E). The data show that encapsulation of DOX in the HCLPN-D nanoparticles could greatly reduce its systemic toxicity after intraperitoneal injection, which is in accordance with the body weight data shown in Figure 7f . 
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